




Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity

Rania Dagher^{1,4}, Varsha Kumar¹, Alan M. Copenhaver¹, Sandra Gallagher¹, Mahboobe Ghaedi¹, Jonathan Boyd², Paul Newbold³, Alison A. Humbles¹ and Roland Kolbeck^{1,4}

¹Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. ²Imaging Core, Discovery Biosciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. ³Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. ⁴R. Dagher and R. Kolbeck contributed equally to this article as lead authors and supervised the work.

Corresponding author: Roland Kolbeck (rkolbeck@spirovant.com)



Shareable abstract (@ERSpublications)

New insights explaining the potent anti-eosinophilic activity of benralizumab, an anti-IL-5R α afucosylated monoclonal antibody with enhanced depleting potency in patients with severe eosinophilic inflammation <https://bit.ly/3yUnsnn>

Cite this article as: Dagher R, Kumar V, Copenhaver AM, *et al.* Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity. *Eur Respir J* 2022; 59: 2004306 [DOI: 10.1183/13993003.04306-2020].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 25 Nov 2020
Accepted: 7 July 2021

Abstract

Background Benralizumab is a humanised, anti-interleukin-5 receptor α monoclonal antibody with anti-eosinophilic activity. Lack of fucose (afucosylation) increases its affinity to CD16a and significantly enhances antibody-dependent cell-mediated cytotoxicity by natural killer (NK) cells. Although benralizumab proved clinically efficacious in clinical trials for patients with severe asthma and hypereosinophilic syndrome, in-depth characterisation of its anti-eosinophilic mechanisms of action remains elusive.

Methods Here, we further investigated the mechanisms involved in benralizumab's anti-eosinophilic activities by employing relevant primary human autologous cell co-cultures and real-time-lapse imaging combined with flow cytometry.

Results In the presence of NK cells, benralizumab induced potent eosinophil apoptosis as demonstrated by the upstream induction of Caspase-3/7 and upregulation of cytochrome *c*. In addition, we uncovered a previously unrecognised mechanism whereby benralizumab can induce eosinophil phagocytosis/efferocytosis by macrophages, a process called antibody-dependent cellular phagocytosis. Using live cell imaging, we unravelled the stepwise processes leading to eosinophil apoptosis and uptake by activated macrophages. Through careful observations of cellular co-culture assays, we identified a novel role for macrophage-derived tumour necrosis factor (TNF) to further enhance benralizumab-mediated eosinophil apoptosis through activation of TNF receptor 1 on eosinophils. TNF-induced eosinophil apoptosis was associated with cytochrome *c* upregulation, mitochondrial membrane depolarisation and increased Caspase-3/7 activity. Moreover, activated NK cells were found to amplify this axis through the secretion of interferon- γ , subsequently driving TNF expression by macrophages.

Conclusions Our data provide deeper insights into the timely appearance of events leading to benralizumab-induced eosinophil apoptosis and suggest that additional mechanisms may contribute to the potent anti-eosinophilic activity of benralizumab *in vivo*. Importantly, afucosylation of benralizumab strongly enhanced its potency for all mechanisms investigated.

